Spitzer W O
McGill University, Montreal, Quebec, Canada.
Am J Obstet Gynecol. 1998 Sep;179(3 Pt 2):S43-50. doi: 10.1053/ob.1998.v179.a93059.
Late in 1995 and early 1996, 4 epidemiologic studies were published that resulted in a crude mean weighted relative risk of approximately 2 when third-generation oral contraceptives were compared with second-generation oral contraceptives as risk factors for venous thromboembolism. This article reviews empirical evidence on bias or systematic error that may have influenced the estimates of association. The Bradford-Hill criteria to distinguish causality from an observed association were used to consider whether third-generation oral contraceptives cause an apparent excess in the occurrence of venous thromboembolism. Bias is more likely than a causal relationship to explain the associations observed for venous thromboembolism. For myocardial infarction, bias may mask the full benefit of third-generation oral contraceptives. For stroke, the question of causality is moot because statistically significant differences between third- and second-generation products have not been detected. The clinical importance and the public health significance of any differences among the various products with respect to adverse cardiovascular outcomes are trivial and undetectable because of the extremely low incidence of those disorders among users of oral contraceptives. The oral contraceptive pill is 99.9% effective when used correctly. All oral contraceptives on the market are safe and getting safer.
1995年末和1996年初,发表了4项流行病学研究,结果显示,当将第三代口服避孕药与第二代口服避孕药作为静脉血栓栓塞的危险因素进行比较时,粗略的平均加权相对风险约为2。本文回顾了可能影响关联估计的偏倚或系统误差的实证证据。采用布拉德福德-希尔标准来区分观察到的关联中的因果关系,以考虑第三代口服避孕药是否会导致静脉血栓栓塞发生率明显过高。偏倚比因果关系更有可能解释观察到的静脉血栓栓塞关联。对于心肌梗死,偏倚可能掩盖了第三代口服避孕药的全部益处。对于中风,因果关系问题尚无定论,因为尚未检测到第三代和第二代产品之间的统计学显著差异。由于口服避孕药使用者中这些疾病的发病率极低,各种产品在不良心血管结局方面的任何差异的临床重要性和公共卫生意义都微不足道且无法检测到。口服避孕药正确使用时的有效率为99.9%。市场上所有的口服避孕药都是安全的,而且越来越安全。